Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06229912 · ClinicalTrials.gov registry record · Phase 2

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

A Phase 2 study of Leukemia and HOX Gene, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT06229912: Recruiting Phase 2 study of Leukemia and HOX Gene, sponsored by M.D. Anderson Cancer Center.

NCT06229912 is a Phase 2 study of Leukemia and HOX Gene that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06229912, a Phase 2 study of Leukemia and HOX Gene, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Conditions Studied

Leukemia HOX Gene

Interventions

  • DRUG Revumenib

Study Locations (2)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-06-04
Est. Completion 2028-12-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT06229912 shows while recruiting

NCT06229912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower).

The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Revumenib is the first listed.

NCT06229912 reports a single indexed study location in New York, Texas.

Frequently Asked Questions

What is clinical trial NCT06229912 about?

NCT06229912 is a clinical study titled "A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes". To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.

What is the current status of trial NCT06229912?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-06-04. Estimated completion is 2028-12-01.

What conditions does trial NCT06229912 study?

This clinical trial studies the following conditions: Leukemia, HOX Gene.

What interventions are being tested in trial NCT06229912?

The interventions under investigation include: Revumenib (DRUG).

Who is sponsoring clinical trial NCT06229912?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06229912 being conducted?

This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06229912's enrollment target sits among peer trials

40 130th of 233 higher than 95 of 233 other Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

  • NCT02106988 · 40 participants · Phase 2

    Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06229912

Source: ClinicalTrials.gov NCT06229912, the US trial registry maintained by the National Library of Medicine. NCT06229912 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.